Frontline Metastatic Pancreatic Cancer - NALIRIFOX, FOLFIRINOX or Gemcitabine–Nab-Paclitaxel: CancerNetwork | September 2026

Introduction:

With three major multidrug regimens available for frontline metastatic pancreatic ductal adenocarcinoma (PDAC), treatment selection has become increasingly nuanced. NALIRIFOX has joined FOLFIRINOX and gemcitabine–nab-paclitaxel as an important first-line option, raising a practical question: should the most active regimen be used upfront, or should certain agents be preserved for later lines?

Why does the first-line choice matter?

Metastatic PDAC can progress rapidly.

A substantial proportion of patients deteriorate before receiving second-line treatment.

Even in the phase III NAPOLI-3 trial, approximately half of patients did not subsequently receive another treatment line.

Therefore, preserving an effective drug for later therapy may be less valuable if the patient never reaches second line.

The experts summarize this pragmatically as:

“Your first shot is typically your best shot.”

Where Does NALIRIFOX Fit?

NALIRIFOX combines:

Liposomal irinotecan + oxaliplatin + 5-FU + leucovorin

In NAPOLI-3, it was directly compared with gemcitabine + nab-paclitaxel and established itself as an effective frontline regimen.

The experts consider NALIRIFOX particularly attractive because of its combination of:

Strong efficacy

Durable disease control

Manageable tolerability

Ability to deliver liposomal irinotecan during the treatment line patients are most likely to receive

NALIRIFOX vs FOLFIRINOX: Important Caveat

There has been no randomized head-to-head trial comparing NALIRIFOX with FOLFIRINOX.

Therefore, statements that NALIRIFOX is equivalent or superior to FOLFIRINOX cannot be considered definitive.

Nevertheless, based on available trial data and clinical experience, the experts regard NALIRIFOX as at least a reasonable alternative to FOLFIRINOX, particularly when tolerability and sustained treatment exposure are considered.

What About Gemcitabine + Nab-Paclitaxel?

Gemcitabine–nab-paclitaxel remains an important frontline option and can preserve fluoropyrimidine/liposomal irinotecan-based therapy for subsequent treatment.

However, the traditional sequencing argument:

Gem–nab-paclitaxel first → liposomal irinotecan + 5-FU later

has an important weakness: many patients with metastatic PDAC will never be sufficiently fit to receive that second line.

Thus, sequencing should not be based solely on preserving drugs for later.

Clinical Decision Framework:

Rather than declaring a universal winner, frontline treatment should incorporate:

Performance status + age/frailty + comorbidities + neuropathy risk + GI toxicity + bilirubin/liver function + patient preference + anticipated ability to receive subsequent therapy

For a fit patient requiring maximal disease control, NALIRIFOX or FOLFIRINOX are compelling options.

Gemcitabine–nab-paclitaxel remains highly relevant when patient characteristics, toxicity considerations or subsequent sequencing favor a gemcitabine-based approach.

Caution:

This is an expert discussion, not a new randomised comparative trial.

Most importantly:

NALIRIFOX vs FOLFIRINOX has never been tested head-to-head.

Cross-trial comparisons are vulnerable to differences in eligibility, patient populations, supportive care and subsequent therapy. Claims that one is definitively superior to the other are therefore premature.

Bottom Line:

In metastatic PDAC, treatment should not be weakened simply to “save” an effective agent for later—many patients never reach second-line therapy. NALIRIFOX is now a strong frontline option alongside FOLFIRINOX and gemcitabine–nab-paclitaxel, but there is no randomised evidence proving superiority over FOLFIRINOX. For fit patients, the priority should be delivering the most appropriate effective therapy upfront while individualising toxicity and future sequencing.